Literature DB >> 19788389

Adenovirus 5-fiber 35 chimeric vector mediates efficient apical correction of the cystic fibrosis transmembrane conductance regulator defect in cystic fibrosis primary airway epithelia.

Ophélia Granio1, Katherine J D Ashbourne Excoffon, Petra Henning, Patricia Melin, Caroline Norez, Gaëlle Gonzalez, Philip H Karp, Maria K Magnusson, Nagy Habib, Leif Lindholm, Frédéric Becq, Pierre Boulanger, Joseph Zabner, Saw-See Hong.   

Abstract

In vivo gene transfer to the human respiratory tract by adenovirus serotype 5 (Ad5) vectors has revealed their limitations related to inefficient gene transfer, host antiviral response, and innate adenoviral toxicity. In the present work, we compared the cytotoxicity and efficiency of Ad5 and a chimeric Ad5F35 vector with respect to CFTR gene transfer to cystic fibrosis (CF) and non-CF human airway epithelial cells. We found that high doses of Ad5 vector had an adverse effect on the function of exogenous and endogenous CFTR. Results obtained with Ad5 capsid mutants suggested that the RGD motifs on the penton base capsomers were responsible for the negative effect on CFTR function. This negative interference did not result from a lower level of biosynthesis and/or altered cellular trafficking of the CFTR protein, but rather from an indirect mechanism of functional blockage of CFTR, related to the RGD integrin-mediated endocytic pathway of Ad5. No negative interference with CFTR was observed for Ad5F35, an Ad5-based vector pseudotyped with fibers from Ad35, a serotype that uses another cell entry pathway. In vitro, Ad5F35 vector expressing the GFP-tagged CFTR (Ad5F35-GFP-CFTR) showed a 30-fold higher efficiency of transduction and chloride channel correction in CFTR-deficient cells, compared with Ad5GFP-CFTR. Ex vivo, Ad5F35-GFP-CFTR had the capacity to transduce efficiently reconstituted airway epithelia from patients with CF (CF-HAE) via the apical surface, restored chloride channel function at relatively low vector doses, and showed relatively stable expression of GFP-CFTR for several weeks.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19788389     DOI: 10.1089/hum.2009.056

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  13 in total

Review 1.  Genetic therapies for cystic fibrosis lung disease.

Authors:  Patrick L Sinn; Reshma M Anthony; Paul B McCray
Journal:  Hum Mol Genet       Date:  2011-03-21       Impact factor: 6.150

2.  Multimerization of adenovirus serotype 3 fiber knob domains is required for efficient binding of virus to desmoglein 2 and subsequent opening of epithelial junctions.

Authors:  Hongjie Wang; ZongYi Li; Roma Yumul; Stephanie Lara; Akseli Hemminki; Pascal Fender; André Lieber
Journal:  J Virol       Date:  2011-04-27       Impact factor: 5.103

Review 3.  Barriers to inhaled gene therapy of obstructive lung diseases: A review.

Authors:  Namho Kim; Gregg A Duncan; Justin Hanes; Jung Soo Suk
Journal:  J Control Release       Date:  2016-05-16       Impact factor: 9.776

4.  Highly differentiated human airway epithelial cells: a model to study host cell-parasite interactions in pertussis.

Authors:  Claudia Guevara; Chengxian Zhang; Jennifer A Gaddy; Junaid Iqbal; Julio Guerra; David P Greenberg; Michael D Decker; Nicholas Carbonetti; Timothy D Starner; Paul B McCray; Frits R Mooi; Oscar G Gómez-Duarte
Journal:  Infect Dis (Lond)       Date:  2015-10-22

5.  Cell entry and trafficking of human adenovirus bound to blood factor X is determined by the fiber serotype and not hexon:heparan sulfate interaction.

Authors:  Stéphanie Corjon; Gaëlle Gonzalez; Petra Henning; Alexei Grichine; Leif Lindholm; Pierre Boulanger; Pascal Fender; Saw-See Hong
Journal:  PLoS One       Date:  2011-05-26       Impact factor: 3.240

6.  Tropism-modification strategies for targeted gene delivery using adenoviral vectors.

Authors:  Lynda Coughlan; Raul Alba; Alan L Parker; Angela C Bradshaw; Iain A McNeish; Stuart A Nicklin; Andrew H Baker
Journal:  Viruses       Date:  2010-10-13       Impact factor: 5.818

Review 7.  New Directions in Pulmonary Gene Therapy.

Authors:  Amber Vu; Paul B McCray
Journal:  Hum Gene Ther       Date:  2020-09       Impact factor: 4.793

8.  Microparticle-mediated transfer of the viral receptors CAR and CD46, and the CFTR channel in a CHO cell model confers new functions to target cells.

Authors:  Gaëlle Gonzalez; Cyrielle Vituret; Attilio Di Pietro; Marc Chanson; Pierre Boulanger; Saw-See Hong
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

9.  Nanoparticles that deliver triplex-forming peptide nucleic acid molecules correct F508del CFTR in airway epithelium.

Authors:  Nicole Ali McNeer; Kavitha Anandalingam; Rachel J Fields; Christina Caputo; Sascha Kopic; Anisha Gupta; Elias Quijano; Lee Polikoff; Yong Kong; Raman Bahal; John P Geibel; Peter M Glazer; W Mark Saltzman; Marie E Egan
Journal:  Nat Commun       Date:  2015-04-27       Impact factor: 14.919

Review 10.  The evolution of adenoviral vectors through genetic and chemical surface modifications.

Authors:  Cristian Capasso; Mariangela Garofalo; Mari Hirvinen; Vincenzo Cerullo
Journal:  Viruses       Date:  2014-02-17       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.